Phio Pharmaceuticals (PHIO) AI Stock Analysis

• Market Cap: $8.78M
• Dividend Yield: N/A
• Average Volume (3M): 6.38M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.16
• Revenue Growth: N/A
• EPS Growth: 81.71%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -0.41
• Shares Outstanding: 4,798,154
• 10 Day Avg. Volume: 1,515,784
• 30 Day Avg. Volume: 6,381,418
• PEG Ratio: -0.30
• Price to Book (P/B): 6.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.52
• Enterprise Value/Market Cap: -0.51
• Enterprise Value/Revenue: -74.77
• Enterprise Value/Gross Profit: 4.49K
• Enterprise Value/Ebitda: 0.16
• 1Y Price Target: $4.00
• Price Target Upside: 117.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 42 Neutral
• Price Target: ―

Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.

Positive Factors

Clinical Study Outcomes

Two patients with CSCC who completed treatment with PH-762 showed a complete response (100% tumor clearance).

Treatment Tolerability

PH-762 intratumoral (IT) injection has been well-tolerated in all enrolled patients, with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects.

Negative Factors

Market Perception

The potential for the PH-762 Phase 1b study to generate data flow that could be positive catalysts through 2025 is underappreciated.

Phio Pharmaceuticals Business Overview & Revenue Model

Company Description

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

How the Company Makes Money

Phio Pharmaceuticals generates revenue through strategic partnerships, research collaborations, and licensing agreements related to its RNAi technology platform. The company aims to out-license its proprietary sd-rxRNA technology to larger pharmaceutical or biotechnology companies, which can incorporate these therapies into their own cancer treatment pipelines. Additionally, Phio may receive milestone payments and royalties from these partnerships based on the successful development and commercialization of its therapeutics. The company might also secure funding through grants and government programs aimed at supporting innovative cancer research.

Phio Pharmaceuticals Financial Statement Overview

Summary

Phio Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing operational losses. The balance sheet shows low leverage, but the cash flow situation is concerning due to consistent cash burn and a reliance on external financing. The company must focus on revenue generation and efficient cash management to improve its financial health.

Income Statement

Phio Pharmaceuticals has consistently reported zero revenue over the years, indicating a lack of product commercialization. The net income remains negative, reflecting persistent losses. The company's inability to generate revenue and its ongoing operational losses are significant concerns.

Balance Sheet

The company maintains a strong equity position relative to its assets, with a high equity ratio indicating minimal leverage. However, the substantial cash burn and diminishing cash reserves are potential risks if new funding is not secured.

Cash Flow

Operating cash flow remains negative, indicative of ongoing operational challenges. While the company has managed to secure financing to cover cash flow needs, the absence of free cash flow growth poses a risk to long-term sustainability.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-1.00K	0.00	-6.33M	-193.00K	-192.00K	-183.00K
	EBIT
-5.18M	-7.39M	-10.82M	-11.46M	-13.51M	-8.79M
	EBITDA
-5.11M	-7.12M	-10.64M	-11.29M	-13.09M	-8.72M
	Net Income Common Stockholders
-6.76M	-7.15M	-10.83M	-11.30M	-13.21M	-8.79M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
13.28M	5.38M	8.49M	11.78M	24.06M	14.24M
	Total Assets
13.44M	5.74M	9.36M	12.81M	25.17M	15.74M
	Total Debt
0.00	0.00	35.00K	305.00K	295.00K	642.00K
	Net Debt
-13.28M	-5.38M	-8.46M	-11.48M	-23.76M	-13.60M
	Total Liabilities
1.27M	1.01M	1.63M	1.98M	3.24M	2.72M
	Stockholders Equity
12.17M	4.72M	7.73M	10.84M	21.93M	13.02M
Cash Flow		Free Cash Flow
-5.79M	-7.11M	-10.75M	-12.25M	-11.91M	-8.82M
	Operating Cash Flow
-5.78M	-7.11M	-10.75M	-12.13M	-11.86M	-8.80M
	Investing Cash Flow
6.00K	8.00K	-5.00K	-121.00K	-51.00K	-19.00K
	Financing Cash Flow
13.17M	4.00M	7.41M	-26.00K	21.72M	16.13M

Phio Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.84
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHIO, the sentiment is Neutral. The current price of 1.84 is below the 20-day moving average (MA) of 1.88, above the 50-day MA of 1.72, and below the 200-day MA of 2.36, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 49.35 is Neutral, neither overbought nor oversold. The STOCH value of 30.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PHIO.

Phio Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.14B	3.06	-43.57%	2.81%	16.81%	-0.12%
OTRK	46 Neutral	$6.62M	―	-215.66%	―	-21.03%	47.41%
PHIO	42 Neutral	$8.78M	―	-76.12%	―	―	81.71%
GTBP	34 Underperform	$5.60M	―	-538.87%	―	―	-26.02%
CELZ		$5.17M	―	-70.45%	―	―	―
AEON	24 Underperform	$6.21M	<0.01	13.29%	―	―	-261.69%
DRMA	15 Underperform	$4.90M	―	-206.26%	―	―	75.68%

Phio Pharmaceuticals Corporate Events

Phio Pharmaceuticals Appoints David Deming to Board

Phio Pharmaceuticals Corp. announced the appointment of David H. Deming to its Board of Directors, effective February 19, 2025. Mr. Deming, with over 30 years of experience in investment banking and asset management, will serve on the Board’s Nominating Committee. This strategic appointment is expected to bolster Phio’s capabilities as it advances its gene silencing technology in the biopharma sector, particularly in immuno-oncology therapeutics.